CY1123305T1 - Υποκατεστημενες ιμιδαζο-κινολινες ως ρυθμιστες nlrp3 - Google Patents
Υποκατεστημενες ιμιδαζο-κινολινες ως ρυθμιστες nlrp3Info
- Publication number
- CY1123305T1 CY1123305T1 CY20201100649T CY201100649T CY1123305T1 CY 1123305 T1 CY1123305 T1 CY 1123305T1 CY 20201100649 T CY20201100649 T CY 20201100649T CY 201100649 T CY201100649 T CY 201100649T CY 1123305 T1 CY1123305 T1 CY 1123305T1
- Authority
- CY
- Cyprus
- Prior art keywords
- nlrp3
- disease
- condition
- disorder
- quinolines
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Optical Communication System (AREA)
- Adhesives Or Adhesive Processes (AREA)
- Transducers For Ultrasonic Waves (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762460677P | 2017-02-17 | 2017-02-17 | |
| US201762490881P | 2017-04-27 | 2017-04-27 | |
| US201762573991P | 2017-10-18 | 2017-10-18 | |
| PCT/US2018/018484 WO2018152396A1 (en) | 2017-02-17 | 2018-02-16 | Substituted imidazo-quinolines as nlrp3 modulators |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1123305T1 true CY1123305T1 (el) | 2021-12-31 |
Family
ID=61283434
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20201100649T CY1123305T1 (el) | 2017-02-17 | 2020-07-16 | Υποκατεστημενες ιμιδαζο-κινολινες ως ρυθμιστες nlrp3 |
Country Status (29)
| Country | Link |
|---|---|
| US (4) | US10533005B2 (https=) |
| EP (2) | EP3510034B1 (https=) |
| JP (1) | JP7003143B6 (https=) |
| KR (1) | KR102329062B1 (https=) |
| CN (1) | CN110325534B (https=) |
| AU (1) | AU2018221076B2 (https=) |
| CA (1) | CA3053949A1 (https=) |
| CL (1) | CL2019002324A1 (https=) |
| CO (1) | CO2019008932A2 (https=) |
| CY (1) | CY1123305T1 (https=) |
| DK (1) | DK3510034T3 (https=) |
| ES (2) | ES2799900T3 (https=) |
| HR (1) | HRP20201087T1 (https=) |
| HU (1) | HUE050965T2 (https=) |
| IL (1) | IL268640B (https=) |
| LT (1) | LT3510034T (https=) |
| ME (1) | ME03801B (https=) |
| MX (1) | MX390065B (https=) |
| MY (1) | MY194054A (https=) |
| PE (1) | PE20191552A1 (https=) |
| PL (1) | PL3510034T3 (https=) |
| PT (1) | PT3510034T (https=) |
| RS (1) | RS60548B1 (https=) |
| SG (1) | SG11201907451XA (https=) |
| SI (1) | SI3510034T1 (https=) |
| SM (1) | SMT202000375T1 (https=) |
| TW (1) | TWI674261B (https=) |
| WO (1) | WO2018152396A1 (https=) |
| ZA (1) | ZA201906104B (https=) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106397592A (zh) * | 2015-07-31 | 2017-02-15 | 苏州康宁杰瑞生物科技有限公司 | 针对程序性死亡配体(pd-l1)的单域抗体及其衍生蛋白 |
| KR102726248B1 (ko) | 2016-07-07 | 2024-11-05 | 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 | 항체-애쥬번트 접합체 |
| TWI674261B (zh) | 2017-02-17 | 2019-10-11 | 美商英能腫瘤免疫股份有限公司 | Nlrp3 調節劑 |
| MY201080A (en) | 2017-07-14 | 2024-02-03 | Innate Tumor Immunity Inc | Nlrp3 modulators |
| ES2988798T3 (es) | 2017-07-24 | 2024-11-21 | Novartis Ag | Compuestos y composiciones para el tratamiento de afecciones asociadas a la actividad de NLRP |
| UY37848A (es) | 2017-08-15 | 2019-03-29 | Inflazome Ltd | Sulfonilureas y sulfoniltioureas útiles como inhibidores de nlrp3 |
| MA49903A (fr) | 2017-08-15 | 2020-06-24 | Inflazome Ltd | Sulfonylureés et sulfonylthioureés en tant qu'inhibiteurs de nlrp3 |
| EP3668843A1 (en) | 2017-08-15 | 2020-06-24 | Inflazome Limited | Sulfonylureas and sulfonylthioureas as nlrp3 inhibitors |
| KR20240152947A (ko) | 2017-10-18 | 2024-10-22 | 인사이트 코포레이션 | Pi3k-감마 저해제로서의 3차 하이드록시기로 치환된 축합된 이미다졸 유도체 |
| CN111315733A (zh) | 2017-11-09 | 2020-06-19 | 英夫拉索姆有限公司 | 新颖磺酰胺甲酰胺化合物 |
| WO2019092171A1 (en) | 2017-11-09 | 2019-05-16 | Inflazome Limited | Novel sulfonamide carboxamide compounds |
| US11905252B2 (en) | 2018-03-02 | 2024-02-20 | Inflazome Limited | Compounds |
| PE20210160A1 (es) | 2018-04-25 | 2021-01-26 | Innate Tumor Immunity Inc | Moduladores de nlrp3 |
| KR102768379B1 (ko) * | 2018-08-16 | 2025-02-13 | 인네이트 튜머 이뮤니티, 인코포레이티드 | 이미다조[4,5-c]퀴놀린 유래 NLRP3-조정제 |
| CN112888677A (zh) | 2018-08-16 | 2021-06-01 | 先天肿瘤免疫公司 | 被取代的4-氨基-1H-咪唑并[4,5-c]喹啉化合物及其改进的制备方法 |
| JP7433291B2 (ja) * | 2018-08-16 | 2024-02-19 | イネイト・テューマー・イミュニティ・インコーポレイテッド | イミダゾ［４，５－ｃ］キノリン誘導体のＮＬＲＰ３モジュレーター |
| CR20250050A (es) | 2018-09-05 | 2025-03-19 | Incyte Corp | Formas cristalinas de un inhibidor de fosfoinositida 3–quinasa (pi3k) (divisional 2021-0165) |
| CN111253390B (zh) * | 2018-11-30 | 2023-10-03 | 四川科伦博泰生物医药股份有限公司 | 并环化合物、其制备方法及用途 |
| EP3911641A1 (en) * | 2019-01-14 | 2021-11-24 | Innate Tumor Immunity, Inc. | Nlrp3 modulators |
| ES2930151T3 (es) * | 2019-01-14 | 2022-12-07 | Innate Tumor Immunity Inc | Moduladores heterocíclicos de NLRP3, para su uso en el tratamiento del cáncer |
| WO2020150116A1 (en) * | 2019-01-14 | 2020-07-23 | Innate Tumor Immunity, Inc. | Nlrp3 modulators |
| US20220056043A1 (en) | 2019-02-19 | 2022-02-24 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Nitrogen-containing fused cyclic compound, preparation method therefor and use thereof |
| AU2020241686A1 (en) | 2019-03-15 | 2021-11-04 | Bolt Biotherapeutics, Inc. | Immunoconjugates targeting HER2 |
| CN116854706B (zh) * | 2019-04-18 | 2025-11-04 | 四川科伦博泰生物医药股份有限公司 | 稠环化合物、其制备方法及用途 |
| UY38687A (es) | 2019-05-17 | 2023-05-15 | Novartis Ag | Inhibidores del inflamasoma nlrp3, composiciones, combinaciones de los mismos y métodos para su uso |
| WO2021126281A1 (en) * | 2019-12-20 | 2021-06-24 | Nammi Therapeutics, Inc. | Formulated and/or co-formulated liposome compositions containing toll-like receptor ("tlr") agonist prodrugs useful in the treatment of cancer and methods thereof |
| CN115244052A (zh) * | 2020-01-10 | 2022-10-25 | 先天肿瘤免疫公司 | Nlrp3调节剂 |
| KR102409345B1 (ko) * | 2020-09-22 | 2022-06-16 | 가톨릭대학교 산학협력단 | Nlrp3 인플라마좀 억제제 및 이의 용도 |
| UY40374A (es) | 2022-08-03 | 2024-02-15 | Novartis Ag | Inhibidores de inflamasoma nlrp3 |
| CN116874340B (zh) * | 2023-07-10 | 2024-04-05 | 湖北航天化学技术研究所 | 一种苯基炸药类含能共晶化合物及其制备方法 |
Family Cites Families (69)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US948029A (en) * | 1909-04-23 | 1910-02-01 | James Harvey Leffler | Reclining-chair. |
| CA1271477A (en) | 1983-11-18 | 1990-07-10 | John F. Gerster | 1h-imidazo[4,5-c]quinolin-4-amines |
| US5389640A (en) | 1991-03-01 | 1995-02-14 | Minnesota Mining And Manufacturing Company | 1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines |
| CA2289219C (en) * | 1991-03-01 | 2003-05-20 | Minnesota Mining And Manufacturing Company | 1-substituted, 2-substituted 1h-imidazo[4,5-c]quinolin-4-amines |
| US5268376A (en) | 1991-09-04 | 1993-12-07 | Minnesota Mining And Manufacturing Company | 1-substituted 1H-imidazo[4,5-c]quinolin-4-amines |
| JPH1180156A (ja) | 1997-09-04 | 1999-03-26 | Hokuriku Seiyaku Co Ltd | １−（置換アリール）アルキル−１ｈ−イミダゾピリジン−４−アミン誘導体 |
| DK1141028T3 (da) | 1998-12-23 | 2010-05-25 | Pfizer | Humane monoklonale antistoffer til CTLA-4 |
| IL148079A0 (en) | 1999-08-24 | 2002-09-12 | Medarex Inc | Human ctla-4 antibodies and compositions containing the same |
| GB0023008D0 (en) | 2000-09-20 | 2000-11-01 | Glaxo Group Ltd | Improvements in vaccination |
| US7927613B2 (en) | 2002-02-15 | 2011-04-19 | University Of South Florida | Pharmaceutical co-crystal compositions |
| MXPA05006740A (es) | 2002-12-20 | 2005-10-05 | 3M Innovative Properties Co | Imidazoquinolinas arilo-sustituidas. |
| JP2006517974A (ja) | 2003-02-13 | 2006-08-03 | スリーエム イノベイティブ プロパティズ カンパニー | Ｉｒｍ化合物およびトル様受容体８に関する方法および組成物 |
| EP2939693A1 (en) | 2003-08-14 | 2015-11-04 | 3M Innovative Properties Company | Lipid-modified immune response modifiers |
| MXPA06002199A (es) | 2003-08-27 | 2006-05-22 | 3M Innovative Properties Co | Imidazoquinolinas sustituidas con grupos ariloxi o arilalquilenoxi. |
| EP1667694B1 (en) | 2003-09-05 | 2010-04-28 | Anadys Pharmaceuticals, Inc. | Tlr7 ligands for the treatment of hepatitis c |
| WO2005051317A2 (en) * | 2003-11-25 | 2005-06-09 | 3M Innovative Properties Company | Substituted imidazo ring systems and methods |
| US7939526B2 (en) | 2003-12-04 | 2011-05-10 | 3M Innovative Properties Company | Sulfone substituted imidazo ring ethers |
| WO2005094531A2 (en) | 2004-03-24 | 2005-10-13 | 3M Innovative Properties Company | Amide substituted imidazopyridines, imidazoquinolines, and imidazonaphthyridines |
| JP2007530579A (ja) * | 2004-06-10 | 2007-11-01 | スリーエム イノベイティブ プロパティズ カンパニー | アミド置換イミダゾピリジン、イミダゾキノリン、およびイミダゾナフチリジン |
| US20080015184A1 (en) * | 2004-06-14 | 2008-01-17 | 3M Innovative Properties Company | Urea Substituted Imidazopyridines, Imidazoquinolines, and Imidazonaphthyridines |
| US8017779B2 (en) | 2004-06-15 | 2011-09-13 | 3M Innovative Properties Company | Nitrogen containing heterocyclyl substituted imidazoquinolines and imidazonaphthyridines |
| US20070259881A1 (en) | 2004-06-18 | 2007-11-08 | Dellaria Joseph F Jr | Substituted Imidazo Ring Systems and Methods |
| US7915281B2 (en) | 2004-06-18 | 2011-03-29 | 3M Innovative Properties Company | Isoxazole, dihydroisoxazole, and oxadiazole substituted imidazo ring compounds and method |
| US20080213308A1 (en) | 2004-09-14 | 2008-09-04 | Nicholas Valiante | Imidazoquinoline Compounds |
| JP2008526757A (ja) | 2004-12-30 | 2008-07-24 | スリーエム イノベイティブ プロパティズ カンパニー | 免疫応答調節剤製剤および方法 |
| CA2597446A1 (en) * | 2005-02-11 | 2006-08-31 | Coley Pharmaceutical Group, Inc. | Substituted imidazoquinolines and imidazonaphthyridines |
| CA2598656A1 (en) | 2005-02-23 | 2006-08-31 | Coley Pharmaceutical Group, Inc. | Hydroxyalkyl substituted imidazoquinoline compounds and methods |
| CA2598695A1 (en) | 2005-02-23 | 2006-09-21 | Coley Pharmaceutical Group, Inc. | Hydroxyalkyl substituted imidazoquinolines |
| CN104356236B (zh) | 2005-07-01 | 2020-07-03 | E.R.施贵宝&圣斯有限责任公司 | 抗程序性死亡配体1(pd-l1)的人单克隆抗体 |
| WO2007079086A1 (en) * | 2005-12-28 | 2007-07-12 | Coley Pharmaceutical Group, Inc. | Pyrazoloalkyl substituted imidazo ring compounds and methods |
| KR20100016289A (ko) | 2007-05-08 | 2010-02-12 | 아스트라제네카 아베 | 면역-조정 특성의 이미다조퀴놀린 |
| HRP20131167T1 (hr) | 2007-06-18 | 2014-01-03 | Merck Sharp & Dohme B.V. | Antitijela za humani receptor programirane smrti pd-1 |
| EP2009002A1 (en) | 2007-06-21 | 2008-12-31 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | New process for the manufacture of 1H-imidazo [4,5-c]-quinoline ring systems |
| AU2009333580B2 (en) | 2008-12-09 | 2016-07-07 | Genentech, Inc. | Anti-PD-L1 antibodies and their use to enhance T-cell function |
| WO2010088924A1 (en) * | 2009-02-06 | 2010-08-12 | Telormedix Sa | Pharmaceutical compositions comprising imidazoquinolin(amines) and derivatives thereof suitable for local administration |
| NZ628923A (en) | 2009-11-24 | 2016-02-26 | Medimmune Ltd | Targeted binding agents against b7-h1 |
| KR101970025B1 (ko) | 2011-04-20 | 2019-04-17 | 메디뮨 엘엘씨 | Ｂ7-ｈ1 및 ｐｄ-1과 결합하는 항체 및 다른 분자들 |
| US8728486B2 (en) | 2011-05-18 | 2014-05-20 | University Of Kansas | Toll-like receptor-7 and -8 modulatory 1H imidazoquinoline derived compounds |
| WO2013033345A1 (en) * | 2011-08-30 | 2013-03-07 | Regents Of The University Of Minnesota | Immunomodulators and immunomodulator conjugates |
| HRP20201595T1 (hr) | 2011-11-28 | 2020-12-11 | Merck Patent Gmbh | Anti-pd-l1 protutijela i njihova uporaba |
| CN113967253A (zh) | 2012-05-15 | 2022-01-25 | 百时美施贵宝公司 | 通过破坏pd-1/pd-l1信号传输的免疫治疗 |
| HK1204557A1 (en) | 2012-05-31 | 2015-11-27 | Sorrento Therapeutics, Inc. | Antigen binding proteins that bind pd-l1 |
| EP2674170B1 (en) | 2012-06-15 | 2014-11-19 | Invivogen | Novel compositions of TLR7 and/or TLR8 agonists conjugated to lipids |
| US9295732B2 (en) | 2013-02-22 | 2016-03-29 | Invivogen | Conjugated TLR7 and/or TLR8 and TLR2 polycationic agonists |
| JP6742903B2 (ja) | 2013-05-02 | 2020-08-19 | アナプティスバイオ インコーポレイティッド | プログラム死−１（ｐｄ−１）に対する抗体 |
| RS59500B1 (sr) | 2013-05-18 | 2019-12-31 | Aduro Biotech Inc | Sastavi i metode za aktiviranje signaliziranja koje je zavisno od „stimulatora gena za interferon“ |
| US9676853B2 (en) | 2013-05-31 | 2017-06-13 | Sorrento Therapeutics, Inc. | Antigen binding proteins that bind PD-1 |
| US9227969B2 (en) | 2013-08-14 | 2016-01-05 | Novartis Ag | Compounds and compositions as inhibitors of MEK |
| EA034666B1 (ru) | 2013-09-13 | 2020-03-04 | Бейджин Свитзерланд Гмбх | Антитело против pd-1 и его применение для лечения рака или вирусной инфекции и фрагмент антитела |
| MY184154A (en) | 2013-12-12 | 2021-03-23 | Shanghai hengrui pharmaceutical co ltd | Pd-1 antibody, antigen-binding fragment thereof, and medical application thereof |
| WO2015095780A1 (en) | 2013-12-20 | 2015-06-25 | The University Of Kansas | Toll-like receptor 8 agonists |
| TWI681969B (zh) | 2014-01-23 | 2020-01-11 | 美商再生元醫藥公司 | 針對ｐｄ-１的人類抗體 |
| SG10201900002QA (en) | 2014-01-24 | 2019-02-27 | Dana Farber Cancer Institue Inc | Antibody molecules to pd-1 and uses thereof |
| CN105233291A (zh) * | 2014-07-09 | 2016-01-13 | 博笛生物科技有限公司 | 用于治疗癌症的联合治疗组合物和联合治疗方法 |
| CN112587672A (zh) | 2014-09-01 | 2021-04-02 | 博笛生物科技有限公司 | 用于治疗肿瘤的抗-pd-l1结合物 |
| GB201418004D0 (en) | 2014-10-10 | 2014-11-26 | Isis Innovation | Polymer adjuvant |
| CN108112254B (zh) | 2015-03-13 | 2022-01-28 | 西托姆克斯治疗公司 | 抗-pdl1抗体、可活化的抗-pdl1抗体、及其使用方法 |
| MA44594B1 (fr) | 2015-05-29 | 2020-09-30 | Memorial Sloan Kettering Cancer Center | Anticorps anti-ctla-4 et méthodes d'utilisation de ceux-ci |
| WO2017024465A1 (en) | 2015-08-10 | 2017-02-16 | Innovent Biologics (Suzhou) Co., Ltd. | Pd-1 antibodies |
| AR105654A1 (es) | 2015-08-24 | 2017-10-25 | Lilly Co Eli | Anticuerpos pd-l1 (ligando 1 de muerte celular programada) |
| KR20180040706A (ko) | 2015-09-01 | 2018-04-20 | 인네이트 튜머 이뮤니티, 인코포레이티드 | 면역억제 시토카인에 대해 증가된 면역 또는 저항성을 갖는 면역 세포 및 그의 용도 |
| CN114605548A (zh) | 2015-09-01 | 2022-06-10 | 艾吉纳斯公司 | 抗-pd-1抗体及其使用方法 |
| CN115252792A (zh) | 2016-01-07 | 2022-11-01 | 博笛生物科技有限公司 | 用于治疗肿瘤的抗-egfr组合 |
| US10730871B2 (en) | 2016-01-28 | 2020-08-04 | Regents Of The University Of Minnesota | Immunomodulators and immunomodulator conjugates |
| CN111491361B (zh) | 2016-02-02 | 2023-10-24 | 华为技术有限公司 | 确定发射功率的方法、用户设备和基站 |
| WO2017132827A1 (en) | 2016-02-02 | 2017-08-10 | Innovent Biologics (Suzhou) Co., Ltd. | Pd-1 antibodies |
| CA3021349A1 (en) | 2016-04-19 | 2017-10-26 | Innate Tumor Immunity, Inc. | Nlrp3 modulators |
| US10533007B2 (en) | 2016-04-19 | 2020-01-14 | Innate Tumor Immunity, Inc. | NLRP3 modulators |
| TWI674261B (zh) | 2017-02-17 | 2019-10-11 | 美商英能腫瘤免疫股份有限公司 | Nlrp3 調節劑 |
-
2018
- 2018-02-14 TW TW107105417A patent/TWI674261B/zh active
- 2018-02-16 CA CA3053949A patent/CA3053949A1/en active Pending
- 2018-02-16 KR KR1020197026922A patent/KR102329062B1/ko active Active
- 2018-02-16 WO PCT/US2018/018484 patent/WO2018152396A1/en not_active Ceased
- 2018-02-16 SM SM20200375T patent/SMT202000375T1/it unknown
- 2018-02-16 ME MEP-2020-149A patent/ME03801B/me unknown
- 2018-02-16 PE PE2019001718A patent/PE20191552A1/es unknown
- 2018-02-16 US US15/898,258 patent/US10533005B2/en active Active
- 2018-02-16 RS RS20200830A patent/RS60548B1/sr unknown
- 2018-02-16 PL PL18707612T patent/PL3510034T3/pl unknown
- 2018-02-16 SG SG11201907451XA patent/SG11201907451XA/en unknown
- 2018-02-16 JP JP2019544636A patent/JP7003143B6/ja active Active
- 2018-02-16 MY MYPI2019004704A patent/MY194054A/en unknown
- 2018-02-16 DK DK18707612.0T patent/DK3510034T3/da active
- 2018-02-16 LT LTEP18707612.0T patent/LT3510034T/lt unknown
- 2018-02-16 PT PT187076120T patent/PT3510034T/pt unknown
- 2018-02-16 HU HUE18707612A patent/HUE050965T2/hu unknown
- 2018-02-16 AU AU2018221076A patent/AU2018221076B2/en active Active
- 2018-02-16 MX MX2019009788A patent/MX390065B/es unknown
- 2018-02-16 SI SI201830085T patent/SI3510034T1/sl unknown
- 2018-02-16 CN CN201880012493.7A patent/CN110325534B/zh active Active
- 2018-02-16 ES ES18707612T patent/ES2799900T3/es active Active
- 2018-02-16 HR HRP20201087TT patent/HRP20201087T1/hr unknown
- 2018-02-16 ES ES20169634T patent/ES2978510T3/es active Active
- 2018-02-16 EP EP18707612.0A patent/EP3510034B1/en active Active
- 2018-02-16 EP EP20169634.1A patent/EP3753938B1/en active Active
-
2019
- 2019-08-12 IL IL268640A patent/IL268640B/en unknown
- 2019-08-16 CO CONC2019/0008932A patent/CO2019008932A2/es unknown
- 2019-08-16 CL CL2019002324A patent/CL2019002324A1/es unknown
- 2019-09-16 ZA ZA2019/06104A patent/ZA201906104B/en unknown
- 2019-11-25 US US16/693,420 patent/US20200157096A1/en not_active Abandoned
-
2020
- 2020-07-16 CY CY20201100649T patent/CY1123305T1/el unknown
-
2021
- 2021-05-06 US US17/313,319 patent/US11827632B2/en active Active
-
2023
- 2023-10-17 US US18/488,092 patent/US12351580B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1123305T1 (el) | Υποκατεστημενες ιμιδαζο-κινολινες ως ρυθμιστες nlrp3 | |
| CY1124612T1 (el) | Συντηγμενοι δικυκλικοι sgc διεγερτες | |
| CY1122966T1 (el) | 5-βρωμο-2,6-δι-(1η-πυραζολ-1-υλ)πυριμιδιν-4-αμινη για χρηση στη θεραπευτικη αγωγη καρκινου | |
| CY1126367T1 (el) | Παραγωγο βενζαζεπινης, μεθοδος παρασκευης, φαρμακευτικη συνθεση και χρηση αυτης | |
| CY1124476T1 (el) | Egfr αναστολεας, και παρασκευη και εφαρμογη αυτου | |
| EA201891565A1 (ru) | Соединения и композиции для лечения состояний, ассоциированных с активностью sting | |
| CL2019001674A1 (es) | Inhibidores de imidazopirazina de tirosina quinasa de bruton. | |
| MX2018012249A (es) | Moduladores de nlpr3. | |
| MX2021005561A (es) | Rad1901 para usarse en el tratamiento de cancer en sujetos con cancer positivo a receptor de estrogeno alfa resistente a farmaco. | |
| DOP2018000146A (es) | Anticuerpos neutralizadores del virus de inmunodeficiencia humana | |
| CL2017003427A1 (es) | Anticuerpos para cd40 | |
| EA201790492A1 (ru) | СОЕДИНЕНИЯ, КОТОРЫЕ ИНГИБИРУЮТ БЕЛОК Mcl-1 | |
| CO2018011064A2 (es) | Inhibidores de bromodominios | |
| MX2019009796A (es) | Compuestos para el tratamiento del cancer. | |
| CY1124243T1 (el) | Αναστολη του ιοντικου διαυλου υποδοχεα παροδικου δυναμικου α1 | |
| MX389672B (es) | Inhibidores de ssao de aminopirimidina | |
| MX2016014248A (es) | Compuestos polifluorados que actuan como inhibidores de la tirosina cinasa de bruton. | |
| CY1123231T1 (el) | Ενωσεις τετραϋδροπυριμιδοδιαζεπινης και τετραϋδροπυριδοδιαζεπινης για θεραπεια πονου και καταστασεων σχετικων με τον πονο | |
| BR112017002263A2 (pt) | inibidores de proteína cinase c e métodos de uso dos mesmos | |
| EA201990400A1 (ru) | Соединения и композиции и их применение | |
| CY1123216T1 (el) | Αναστολεις της gls1 για την αντιμετωπιση νοσων | |
| CU24608B1 (es) | Compuestos de dihidrooxadiazinonas sustituidas útiles en el tratamiento de enfermedades hiperproliferativas y métodos para preparar dichos compuestos | |
| CY1123880T1 (el) | Καινοτομοι 5-ητ2 ανταγωνιστες | |
| EA202191476A1 (ru) | Гетероароматические соединения в качестве ингибиторов ванина | |
| EA201991196A1 (ru) | Претерпевшие самосборку диблок-сополимеры, состоящие из pegmema и несущих лекарственное средство полимерных сегментов |